Shared treatment decisions for vasculitis patients
Part of Heart & circulation, Immune system & allergy, Skin clinical trials.
This study brings together patients with ANCA-associated vasculitis (AAV) and their doctors to talk about how they make treatment decisions together. The goal is to understand what matters to patients so care can be more collaborative.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ANCA-associated vasculitis.
- You are 18 years old or older.
- You can understand and speak English well enough to join a discussion.
- You live in the UK or Ireland.
- You are able to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding avacopan, a medication that helps calm the immune system, to usual treatment can improve kidney function in people with a type of blood vessel inflammation called vasculitis that affects the kidneys. It's for people with severe kidney involvement who are starting standard treatment.
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
This trial uses a special PET scan to look at inflammation in blood vessels and check heart disease risk in people with active ANCA-associated vasculitis (AAV). It may help doctors understand how to better manage heart health during treatment.
This study compares two ways of managing ANCA-associated vasculitis (inflammation of blood vessels) when ANCA antibodies reappear after remission. One approach is close monitoring with blood tests, and the other is giving rituximab infusions right away to prevent a flare-up. It aims to find out which strategy better prevents disease relapse.
This trial tests a new cell therapy called CT1192 for people with ANCA-associated vasculitis, an autoimmune disease that causes blood vessel inflammation. The therapy aims to reset the immune system to stop the disease, and this early study focuses on safety and how the cells work in the body.
This study is for people with certain rheumatic conditions (like arthritis, lupus, or vasculitis) and for healthy volunteers. It aims to learn more about these diseases and improve how they are treated.
Hear when a new ANCA Associated Vasculitis (AAV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.